These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1879086)

  • 61. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM; Kayser C; Pucinelli ML; Andrade LE
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [TBL] [Abstract][Full Text] [Related]  

  • 63. New prospects for the treatment of Raynaud's phenomenon using a serotoninergic S2 receptor antagonist (ketanserin) and stable derivatives of prostacyclin.
    Pola P; Tondi P; Serricchio M; Favuzzi A; Gerardino L
    Angiology; 1993 Feb; 44(2):123-8. PubMed ID: 8434805
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects.
    Warot D; Berlin I; Aymard G; Ankri A; Fabry C; Besse B; Lechat P; Diquet B
    Fundam Clin Pharmacol; 2000; 14(3):231-6. PubMed ID: 15602800
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2)].
    Cabane J; Boue F; Godeau P; Lecompte T; Charpentier MC; Samama M; Nebout T
    Rev Med Interne; 1985 Dec; 6(5):581-9. PubMed ID: 3914023
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prolonged remission in Raynaud's phenomenon after prostacyclin infusion.
    Bellucci S; Kedra AW; Courmelle JM; Maclouf J; Boizard B; Dosquet-Bernard C; Tobelem G; Caen JP
    Scand J Rheumatol; 1986; 15(4):392-8. PubMed ID: 3547631
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome.
    Belch JJ; McLaren M; Anderson J; Lowe GD; Sturrock RD; Capell HA; Forbes CD; Mikhailidis DP; Jeremy JY; Dandona P
    Prostaglandins Leukot Med; 1985 Jun; 18(3):401-2. PubMed ID: 3895252
    [No Abstract]   [Full Text] [Related]  

  • 68. Cicaprost inhibits metastases of animal tumors.
    Schirner M; Schneider MR
    Prostaglandins; 1991 Nov; 42(5):451-61. PubMed ID: 1763201
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A preliminary double-blind cross-over trial of lipo-PGI2, a prostacyclin derivative incorporated in lipid microspheres, in cerebral infarction.
    Hoshi K; Mizushima Y
    Prostaglandins; 1990 Aug; 40(2):155-64. PubMed ID: 2217831
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).
    Dowd PM; Martin MF; Cooke ED; Bowcock SA; Jones R; Dieppe PA; Kirby JD
    Br J Dermatol; 1982 Jan; 106(1):81-9. PubMed ID: 7037038
    [No Abstract]   [Full Text] [Related]  

  • 71. The stable prostacyclin analogue Cicaprost inhibits metastasis to lungs and lymph nodes in the 13762NF MTLn3 rat mammary carcinoma.
    Schirner M; Lichtner RB; Schneider MR
    Clin Exp Metastasis; 1994 Jan; 12(1):24-30. PubMed ID: 8287616
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antiatherosclerotic properties of oral cicaprost in hypercholesterolemic rabbits.
    Braun M; Sarbia M; Kienbaum P; Hohlfeld T; Weber A; Schrör K
    Agents Actions Suppl; 1992; 37():282-8. PubMed ID: 1632302
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synthesis of a new chemically stable prostacyclin analogue with high and long-lasting activity.
    Iseki K; Kanayama T; Hayasi Y; Shibasaki M
    Chem Pharm Bull (Tokyo); 1990 Jun; 38(6):1769-71. PubMed ID: 2208396
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors.
    Schneider MR; Schirner M; Lichtner RB; Graf H
    Breast Cancer Res Treat; 1996; 38(1):133-41. PubMed ID: 8825130
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rodent model of systemic mammary tumor disease by surgical removal of the spontaneously metastasizing SMT2A mammary carcinoma: inhibitory effect of the stable prostacyclin analogue cicaprost on occult metastasis.
    Schirner M; Schneider MR
    Int J Cancer; 1995 Jul; 62(2):205-9. PubMed ID: 7622297
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cicaprost inhibits collagen-induced platelet accumulation in rat lungs for some hours.
    Nowak G; Bucha E
    Agents Actions Suppl; 1995; 45():101-6. PubMed ID: 7536381
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome.
    Kahan A; Weber S; Amor B; Menkes CJ
    Lancet; 1983 Mar; 1(8323):538. PubMed ID: 6131248
    [No Abstract]   [Full Text] [Related]  

  • 78. Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of patients with progressive scleroderma.
    Keller J; Kaltenecker A; Schricker KT; Neidhardt B; Hornstein OP
    Arch Dermatol Res; 1985; 277(4):323-5. PubMed ID: 2408588
    [No Abstract]   [Full Text] [Related]  

  • 79. The effect of a prostacyclin analogue (Iloprost) on skin temperature.
    Drury JK; Belch JJ; McGregor M; Forbes CD
    Prostaglandins Leukot Med; 1985 Sep; 19(3):301-3. PubMed ID: 2414783
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Raynaud's disease and prostacyclin.
    Kennerly D
    Ann Intern Med; 1983 Feb; 98(2):258. PubMed ID: 6337542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.